ZA200700578B - Method for treating nervous system disorders and conditions - Google Patents

Method for treating nervous system disorders and conditions

Info

Publication number
ZA200700578B
ZA200700578B ZA200700578A ZA200700578A ZA200700578B ZA 200700578 B ZA200700578 B ZA 200700578B ZA 200700578 A ZA200700578 A ZA 200700578A ZA 200700578 A ZA200700578 A ZA 200700578A ZA 200700578 B ZA200700578 B ZA 200700578B
Authority
ZA
South Africa
Prior art keywords
conditions
nervous system
system disorders
treating nervous
treating
Prior art date
Application number
ZA200700578A
Inventor
Arthur Jay Cohn
Darlene Coleman Deecher
Magid A Abou-Gharbia
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ZA200700578B publication Critical patent/ZA200700578B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
ZA200700578A 2004-07-22 2007-01-19 Method for treating nervous system disorders and conditions ZA200700578B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59020304P 2004-07-22 2004-07-22

Publications (1)

Publication Number Publication Date
ZA200700578B true ZA200700578B (en) 2010-06-30

Family

ID=35149631

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200700578A ZA200700578B (en) 2004-07-22 2007-01-19 Method for treating nervous system disorders and conditions

Country Status (14)

Country Link
US (2) US20060020015A1 (en)
EP (1) EP1773320A1 (en)
JP (1) JP2008507550A (en)
KR (1) KR20070034126A (en)
CN (1) CN101410106A (en)
AU (1) AU2005266994A1 (en)
BR (1) BRPI0512186A (en)
CA (1) CA2574310A1 (en)
IL (1) IL180731A0 (en)
MX (1) MX2007000853A (en)
NO (1) NO20070912L (en)
RU (1) RU2007102292A (en)
WO (1) WO2006012474A1 (en)
ZA (1) ZA200700578B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080081834A1 (en) 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
EP1773321A2 (en) * 2004-07-22 2007-04-18 Wyeth Method for treating nervous system disorders and conditions
MX2007000851A (en) * 2004-07-22 2007-03-26 Wyeth Corp Method for treating nervous system disorders and conditions.
US8000005B2 (en) * 2006-03-31 2011-08-16 Prysm, Inc. Multilayered fluorescent screens for scanning beam display systems
WO2007013936A2 (en) * 2005-07-21 2007-02-01 Wyeth Method for treating nervous system disorders and conditions
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
US9566264B2 (en) 2013-07-01 2017-02-14 Euthymics Bioscience, Inc. Combinations and methods

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3166571A (en) * 1962-06-06 1965-01-19 American Cyanamid Co 1-phenyl-1, 2-cyclopropane dicarboximides
US3344026A (en) * 1966-05-16 1967-09-26 American Cyanamid Co Dosage unit composition of 1-(p-chlorophenyl)-1, 2-cyclopropanedicarboximide for relief of depression
US3892772A (en) * 1973-12-04 1975-07-01 American Cyanamid Co Isomer of 1-(p-chlorophenyl)-1,2-cyclopropanedicarboximide and method of use
US4088652A (en) * 1975-07-31 1978-05-09 American Cyanamid Company Acylazabicyclohexanes
US4131611A (en) * 1975-07-31 1978-12-26 American Cyanamid Company Azabicyclohexanes
US4118417A (en) * 1977-06-23 1978-10-03 American Cyanamid Company Process for resolving cis-1-substituted phenyl-1,2-cyclopropanedicarboxylic acids
GR72713B (en) * 1976-09-15 1983-12-01 American Cyanamid Co
US4118393A (en) * 1977-06-23 1978-10-03 American Cyanamid Company Phenyl azabicyclohexanones
US4435419A (en) * 1981-07-01 1984-03-06 American Cyanamid Company Method of treating depression using azabicyclohexanes
EP0114033B1 (en) * 1982-12-21 1988-10-12 Ciba-Geigy Ag Substituted azabicycloalkanes, their use, pharmaceutical preparations containing these compounds and process for preparing these compounds
US6204284B1 (en) * 1991-12-20 2001-03-20 American Cyanamid Company Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
DE19919336A1 (en) * 1999-04-27 2000-11-16 Consortium Elektrochem Ind Hydrolysis of thiazolidine derivative using acidic cation exchanger, giving 2-aminomercaptan derivative, e.g. cysteine or penicillamine, and carbonyl compound in high yield and purity
US6372919B1 (en) * 2001-01-11 2002-04-16 Dov Pharmaceutical, Inc. (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent
KR100875610B1 (en) * 2001-02-12 2008-12-26 와이어쓰 Novel Succinate Salts of O-Desmethyl-Velafaxine
EP1266659A1 (en) * 2001-06-11 2002-12-18 Pantarhei Bioscience B.V. Pyridoxal in combination with serotonin re-uptake inhibitor for the treatment of hot flushes
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
UA77234C2 (en) * 2001-12-05 2006-11-15 Wyeth Corp Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants)
MXPA04005305A (en) * 2001-12-05 2004-09-13 Wyeth Corp Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof.
US20040152710A1 (en) * 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
FR2851163B1 (en) * 2003-02-14 2007-04-27 USE OF DEXTROGYAN ENANTIOMER OF MILNACIPRAN FOR THE PREPARATION OF A MEDICINAL PRODUCT
EP1773321A2 (en) * 2004-07-22 2007-04-18 Wyeth Method for treating nervous system disorders and conditions

Also Published As

Publication number Publication date
BRPI0512186A (en) 2008-02-19
WO2006012474A1 (en) 2006-02-02
NO20070912L (en) 2007-04-20
US20060020015A1 (en) 2006-01-26
MX2007000853A (en) 2007-03-26
KR20070034126A (en) 2007-03-27
EP1773320A1 (en) 2007-04-18
US20120010260A1 (en) 2012-01-12
IL180731A0 (en) 2007-07-04
CA2574310A1 (en) 2006-02-02
RU2007102292A (en) 2008-08-27
JP2008507550A (en) 2008-03-13
AU2005266994A1 (en) 2006-02-02
CN101410106A (en) 2009-04-15

Similar Documents

Publication Publication Date Title
EP1799119A4 (en) Device and method for treating weight disorders
EP1683067A4 (en) Method for screening and treating disorders
IL179864A0 (en) Compounds and methods for treating seizure and paroxysmal disorders
HK1118716A1 (en) Method and composition for treating central nervous system disorders
EP1651164A4 (en) Composition and method for treating neurological disorders
EP1545700A4 (en) Methods for treating central nervous system damage
ZA200610661B (en) Compositions and methods for treating neurological disorders
EP1863562A4 (en) Method of treating depression, mood disorders and anxiety disorders using neuromodulation
EP1603548A4 (en) Method and composition for treating neurodegenerative disorders
IL180342A0 (en) Compositions and methods for treating eye disorders and conditions
IL183985A0 (en) Methods for treating autoimmune disorders
IL181922A0 (en) Method for treating vasculitis
EP1834419A4 (en) Method and system for targeted broadcasting
IL180732A0 (en) Method for treating nervous system disorders and conditions
GB0617734D0 (en) Method of treating peripheral nerve disorders
EP1786465A4 (en) Methods for detecting and treating autoimmune disorders
ZA200705502B (en) System and method for diagnosis of brainstem disorders
ZA200700578B (en) Method for treating nervous system disorders and conditions
ZA200701560B (en) System and method for treating wastewater
IL162288A0 (en) Compositions and methods for treating neurodegenerative disorders
IL193697A0 (en) Methods for treating cognitive and other disorders
AU2003300042A1 (en) Method and system for treating depressive and anxiety disorders
ZA200700580B (en) Method for treating nervous system disorders and conditions
EP1782821A4 (en) Drug and method for improving brain function
EP1695061A4 (en) Method for treating neurological disorders